jcp conference-coverage

Conference Coverage

Hospital Costs and Health Care Resource Utilization for Chimeric Antigen T-Cell Therapy and Stem Cell Transplant in Patients with Large B-Cell Lymphoma in the United States

12/12/2022

Katie Herman ;

At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...

At the 64th ASH Annual Meeting...

12/12/2022

Journal of Clinical Pathways

Conference Coverage

Cost-Effectiveness Analyses of Ibrutinib vs Acalabrutinib vs Zanubrutinib as First-line Treatment in Patients With Chronic Lymphocytic Leukemia

12/12/2022

Katie Herman ;

At the 64th ASH Annual Meeting and Exposition, Neda Alrawashdh, PharmD, presented a network meta-analysis of three BTKis in terms of progression-free survival in support of cost-effectiveness analyses from the US payer perspective.

At the 64th ASH Annual Meeting...

12/12/2022

Journal of Clinical Pathways

Conference Coverage

BME Signatures at Baseline and During Treatment Enable Risk Stratifications of Patients With Multiple Myeloma

12/12/2022

Craig Ostroff ;

In a presentation at the 64th ASH Annual Meeting and Exposition, Simon Steiger, PhD, and colleagues presented a longitudinal study in which they attempted to associate BME samples with multiple myeloma cytogenic and molecular subgroups.

In a presentation at the 64th...

12/12/2022

Journal of Clinical Pathways

Conference Coverage

Isatuximab + Carfilzomib and Dexamethasone in Early vs Late Relapsed Multiple Myeloma

12/12/2022

Katie Herman ;

Thomas Martin, MD, presented at the 64th ASH Annual Meeting and Exposition a subgroup analysis of the phase 3 IKEMA study which examined updated efficacy and safety of isatuximab + carfilzomib (K) and dexamethasone (d) vs Kd in patients with...

Thomas Martin, MD, presented at...

12/12/2022

Journal of Clinical Pathways

Conference Coverage

Comparing BTKis Acalabrutinib and Ibrutinib in Real-World Analysis of Patients With CLL

12/12/2022

Craig Ostroff ;

At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.

At the 64th ASH Annual Meeting...

12/12/2022

Journal of Clinical Pathways

Conference Coverage

High-Risk Lesions: A Consistent Predictor of Ultra-High Risk Multiple Myeloma

12/11/2022

Katie Herman ;

Martin F Kaiser, MD, FRCP, FRCPath, and colleagues presented at the 2022 ASH Annual Meeting and Exposition to discuss their meta-analysis of randomized clinical trials with extended molecular profiling data for patients with newly diagnosed...

Martin F Kaiser, MD, FRCP,...

12/11/2022

Journal of Clinical Pathways

Conference Coverage

Molecular Variants Associated With Resistance to a Quadruplet Treatment Combination in Newly Diagnosed Multiple Myeloma

12/11/2022

Katie Herman ;

At the 2022 ASH Annual Meeting, Francesco Maura, MD, and colleagues investigated the molecular variants associated with resistance to a quadruplet treatment combination in patients with newly diagnosed multiple myeloma.

At the 2022 ASH Annual Meeting,...

12/11/2022

Journal of Clinical Pathways

Conference Coverage

Racial and Ethnic Differences in Clinical Outcomes Among Patients With Multiple Myeloma Treated with CAR T Therapy

12/10/2022

Craig Ostroff ;

At the 64th ASH Annual Meeting and Exposition, Lauren C Peres, PhD, MPH, and colleagues explore the racial and ethnic differences in safety, efficacy, and outcomes among patients with relapsed/refractory multiple myeloma who were treated with...

At the 64th ASH Annual Meeting...

12/10/2022

Journal of Clinical Pathways

Conference Coverage

No Evidence That BCMA Expression Is Completely Lost Following Belamaf Treatment in Patients With RRMM

12/10/2022

Craig Ostroff ;

In a presentation at the 64th Annual ASH Meeting and Exposition, Daniel E Lowther, PhD, and colleagues discuss their study to determine if immune impairment and complete target loss were seen in patients with relapsed/refractory multiple...

In a presentation at the 64th...

12/10/2022

Journal of Clinical Pathways

Conference Coverage

Updated, Longer-term Efficacy Data Following Subsequent Therapy in ICARIA-MM

12/10/2022

Craig Ostroff ;

Paul G Richardson, MD, and colleagues presented a study at the 64th ASH Annual Meeting and Exposition and discussed updated and longer-term efficacy data regarding multiple lines of therapy subsequent to ICARIA-MM.

Paul G Richardson, MD, and...

12/10/2022

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Update: Impact on NSCLC Landscape

11/15/2024

The updated 2024 NCCN Guidelines® recommend broad genomic testing and the need for multidisciplinary care to accurately diagnose and treat non-small cell lung cancer. View this special report to learn more.

The updated 2024 NCCN...

11/15/2024

Journal of Clinical Pathways

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products